Submit to Nutrients Review for Nutrients Propose a Special Issue

Journal Menu

Journal Browser

► Journal Browser

Prebiotics, Probiotics, and Gut Microbiota with Chronic Disease—2nd Edition

Special Issue Editors
Special Issue Information
Keywords
Benefits of Publishing in a Special Issue
Published Papers

A special issue of Nutrients (ISSN 2072-6643). This special issue belongs to the section "Prebiotics and Probiotics".

Deadline for manuscript submissions: closed (25 January 2025) | Viewed by 10408

Share This Special Issue

Special Issue Editor

Dr. Qingsen Shang

E-Mail Website
Guest Editor

Key Laboratory of Marine Drugs of Ministry of Education, and Shandong Provincial Key Laboratory of Glycoscience and Glycotechnology, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China
Interests: gut microbiota; marine polysaccharides; colitis; inflammatory bowel disease; fermentation; prebiotics; probiotics; obesity; diabetes; carbohydrate-based drugs
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Chronic diseases, including heart disease, stroke, cancer, type 2 diabetes, obesity, inflammatory bowel diseases, and arthritis are the leading causes of death and disability worldwide. Previous studies have demonstrated a pivotal role of gut microbiota in the pathogenesis of chronic diseases. However, we are still at the very beginning of understanding the complex interactions between gut microbiota and the development of chronic diseases. In this Special Issue of Nutrients, we sincerely invite you and your colleagues to submit research articles or informative reviews aiming to elucidate the complex interactions between gut microbiota and different chronic diseases. Specifically, we would like to understand how specific gut microbes work to contribute to or help to prevent the development of chronic diseases. Additionally, we would also like to advance our current understanding of the beneficial effects of prebiotic and probiotics on chronic diseases. Research articles and reviews to be considered for publication in this Special Issue of Nutrients should focus on the following topics:

Use of prebiotic and probiotics for the prevention and treatment of chronic diseases;
Pathogenetic gut bacteria that could contribute to the development of chronic diseases;
Modulatory effects of prebiotic and probiotics on the dysbiotic microbiota of chronic diseases;
Use of synbiotics and postbiotics for the prevention and treatment of chronic diseases;
Development of live biotherapeutic products for the prevention and treatment of chronic diseases;
Novel nutrition therapies that could be used for the prevention and treatment of chronic diseases by targeting gut microbiota;
The effects of different gut bacterial metabolites on the development of chronic diseases;
Fecal microbiota transplantation for the management of chronic diseases;
Natural products that could be used for the treatment of chronic diseases by targeting gut dysbiosis.

Dr. Qingsen Shang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nutrients is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

prebiotics
probiotics
synbiotics
postbiotics
microbiota
chronic disease
gut dysbiosis
fecal microbiota transplantation
gut bacterial metabolites
live biotherapeutic products
next-generation prebiotics
next-generation probiotics

Benefits of Publishing in a Special Issue

Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (6 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Review

12 pages, 8239 KiB

Open AccessArticle

Bacteroides salyersiae Is a Candidate Probiotic Species with Potential Anti-Colitis Properties in the Human Colon: First Evidence from an In Vivo Mouse Model

by Wei Dai, Youjing Lv, Min Quan, Mingfeng Ma, Qingsen Shang and Guangli Yu

Nutrients 2024, 16(17), 2918; https://doi.org/10.3390/nu16172918 - 1 Sep 2024

Cited by 2 | Viewed by 1560

Abstract

Previous studies have indicated a critical role of intestinal bacteria in the pathogenesis of ulcerative colitis (UC). B. salyersiae is a commensal species from the human gut microbiota. However, what effect it has on UC development has not been investigated. In the present study, we explored this issue and demonstrated for the first time that oral administration of B. salyersiae CSP6, a bacterium previously isolated from the fecal sample of a healthy individual, protected against dextran sulfate sodium (DSS)-induced colitis in C57BL/6J mice. In particular, B. salyersiae CSP6 improved mucosal damage and attenuated gut dysbiosis in the colon of DSS-fed mice. Specifically, B. salyersiae CSP6 decreased the population of pathogenic Escherichia-Shigella spp. and increased the abundance of probiotic Dubosiella spp. and Bifidobacterium pseudolongum. Additionally, by reshaping the colonic microbiota, B. salyersiae CSP6 remarkably increased the fecal concentrations of equol, 8-deoxylactucin, and tiglic acid, three beneficial metabolites that have been well documented to exert strong anti-inflammatory effects. Altogether, our study provides novel evidence that B. salyersiae is a candidate probiotic species with potential anti-colitis properties in the human colon, which has applications for the development of next-generation probiotics. Full article

(This article belongs to the Special Issue Prebiotics, Probiotics, and Gut Microbiota with Chronic Disease—2nd Edition)

► Show Figures

Figure 1

17 pages, 877 KiB

Open AccessArticle

Use of Dietary Supplements among Polish Children with Inflammatory Bowel Disease: A Two-Center Pilot Study

by Monika Maćków, Agnieszka Kozioł-Kozakowska, Magdalena Szeląg, Tomasz Pytrus, Ewa Raczkowska, Katarzyna Neubauer, Ireneusz Zawiślak, Robert Gajda, Marta Habánová and Andrzej Stawarski

Nutrients 2024, 16(16), 2762; https://doi.org/10.3390/nu16162762 - 19 Aug 2024

Viewed by 1176

Abstract

Inflammatory bowel disease (IBD) includes Crohn’s disease (CD) and ulcerative colitis (UC). These diseases are characterized by inflammation, which may be a consequence of changes in the intestinal microbiota and lead to mineral and vitamin deficiencies. The aims of this study were to determine the level of dietary supplement intake in children with IBD and to determine the influence of factors such as sex, nutritional status, diet, and other comorbidities on supplement intake. The study was conducted from May 2022 to September 2023 and was a prospective study. The group of children with IBD that ultimately qualified for the study numbered 96, and the control group numbered 30. The children who participated in the study were aged 4–18 years. Most parents of children with IBD (81.4%) declared that they use supplementation for their children, while 75% of parents of children without IBD declared giving their children nutritional supplements. Vitamins in both groups were most often given to children as dietary supplements (p = 0.018), including vitamin D. Depending on the diet used, the intake of vitamin B6 (p = 0.018), vitamin E (p = 0.040) and iron (p = 0.006) was significantly different among children with IBD. Statistical significance (p = 0.021) was observed for supplementation use and disease stage among children with IBD. For 80.2% of parents of children with IBD, the main reason for using supplements was a doctor’s recommendation. In the control group, 43.3% of parents indicated that the main reason for using supplements was to correct nutritional deficiencies. Supplementation was common in both groups, but attention should be paid to other current diseases in children with IBD and to nutritional status. In our opinion, educating parents about supplementation is important, especially among parents of children with IBD. Full article

(This article belongs to the Special Issue Prebiotics, Probiotics, and Gut Microbiota with Chronic Disease—2nd Edition)

► Show Figures

Figure 1

17 pages, 4747 KiB

Open AccessArticle

Effect of Mutant and Engineered High-Acetate-Producing Saccharomyces cerevisiae var. boulardii Strains in Dextran Sodium Sulphate-Induced Colitis

by Sara Deleu, Inge Jacobs, Jorge F. Vazquez Castellanos, Sare Verstockt, Bruna Trindade de Carvalho, Ana Subotić, Bram Verstockt, Kaline Arnauts, Lowie Deprez, Eva Vissers, Matthias Lenfant, Greet Vandermeulen, Gert De Hertogh, Kristin Verbeke, Gianluca Matteoli, Geert R. B. Huys, Johan M. Thevelein, Jeroen Raes and Séverine Vermeire

Nutrients 2024, 16(16), 2668; https://doi.org/10.3390/nu16162668 - 13 Aug 2024

Cited by 2 | Viewed by 1912

Abstract

Acetate-producing Saccharomyces cerevisiae var. boulardii strains could exert improved effects on ulcerative colitis, which here, was preclinically evaluated in an acute dextran sodium sulphate induced model of colitis. Nine-week-old female mice were divided into 12 groups, receiving either drinking water or 2.75% dextran sodium sulphate for 7 days, combined with a daily gavage of various treatments with different levels of acetate accumulation: sham control (phosphate buffered saline, no acetate), non-probiotic control (Baker’s yeast, no acetate), probiotic control (Enterol^®, transient acetate), and additionally several Saccharomyces cerevisiae var. boulardii strains with respectively no, high, and extra-high acetate accumulation. Disease activity was monitored daily, and feces samples were collected at different timepoints. On day 14, the mice were sacrificed, upon which blood and colonic tissue were collected for analysis. Disease activity in inflamed mice was lower when treated with the high-acetate-producing strain compared to sham and non-probiotic controls. The non-acetate-producing strain showed higher disease activity compared to the acetate-producing strains. Accordingly, higher histologic inflammation was observed in non- or transient-acetate-producing strains compared to the sham control, whereas this increase was not observed for high- and extra-high-acetate-producing strains upon induction of inflammation. These anti-inflammatory findings were confirmed by transcriptomic analysis of differentially expressed genes. Moreover, only the strain with the highest acetate production was superior in maintaining a stable gut microbial alpha-diversity upon inflammation. These findings support new possibilities for acetate-mediated management of inflammation in inflammatory bowel disease by administrating high-acetate-producing Saccharomyces cerevisae var. boulardii strains. Full article

(This article belongs to the Special Issue Prebiotics, Probiotics, and Gut Microbiota with Chronic Disease—2nd Edition)

► Show Figures

Graphical abstract

Review

Jump to: Research

24 pages, 2656 KiB

Open AccessReview

The Link Between Dysbiosis, Inflammation, Oxidative Stress, and Asthma—The Role of Probiotics, Prebiotics, and Antioxidants

by Paulina Kleniewska and Rafał Pawliczak

Nutrients 2025, 17(1), 16; https://doi.org/10.3390/nu17010016 - 24 Dec 2024

Viewed by 1034

Abstract

Background: Asthma (a chronic inflammatory disease of the airways) is characterized by a variable course, response to treatment, and prognosis. Its incidence has increased significantly in recent decades. Unfortunately, modern lifestyle and environmental factors contribute to the further increase in the incidence of this disease. Progressive industrialization and urbanization, widespread use of antibiotic therapy, excessive sterility and inappropriate, highly processed diets are some of the many risk factors that are relevant today. Over the years, a lot of evidence has been gathered showing the influence of microorganisms of the gut or airways on human health. Studies published in recent years indicate that dysbiosis (microbial imbalance) and oxidative stress (pro-oxidant–antioxidant imbalance) are important elements of the pathogenesis of this inflammatory disease. Scientists have attempted to counteract the effects of this process by using probiotics, prebiotics, and antioxidants. The use of probiotic microorganisms positively modulates the immune system by maintaining homeostasis between individual fractions of immune system cells. Moreover, recently conducted experiments have shown that probiotics have antioxidant, anti-inflammatory, and protective properties in oxidative stress (OS). The aim of this study is to present the current state of knowledge on the role of dysbiosis and OS in the pathogenesis of asthma. Conclusions: This review highlights the importance of using probiotics, prebiotics, and antioxidants as potential strategies to support the treatment and prevention of this disease. Full article

(This article belongs to the Special Issue Prebiotics, Probiotics, and Gut Microbiota with Chronic Disease—2nd Edition)

► Show Figures

Figure 1

31 pages, 2969 KiB

Open AccessReview

Harnessing Prebiotics to Improve Type 2 Diabetes Outcomes

by Oana C. Iatcu, Sevag Hamamah and Mihai Covasa

Nutrients 2024, 16(20), 3447; https://doi.org/10.3390/nu16203447 - 11 Oct 2024

Cited by 2 | Viewed by 2117

Abstract

The gut microbiota, a complex ecosystem of microorganisms in the human gastrointestinal tract (GI), plays a crucial role in maintaining metabolic health and influencing disease susceptibility. Dysbiosis, or an imbalance in gut microbiota, has been linked to the development of type 2 diabetes mellitus (T2DM) through mechanisms such as reduced glucose tolerance and increased insulin resistance. A balanced gut microbiota, or eubiosis, is associated with improved glucose metabolism and insulin sensitivity, potentially reducing the risk of diabetes-related complications. Various strategies, including the use of prebiotics like inulin, fructooligosaccharides, galactooligosaccharides, resistant starch, pectic oligosaccharides, polyphenols, β-glucan, and Dendrobium officinale have been shown to improve gut microbial composition and support glycemic control in T2DM patients. These prebiotics can directly impact blood sugar levels while promoting the growth of beneficial bacteria, thus enhancing glycemic control. Studies have shown that T2DM patients often exhibit a decrease in beneficial butyrate-producing bacteria, like Roseburia and Faecalibacterium, and an increase in harmful bacteria, such as Escherichia and Prevotella. This review aims to explore the effects of different prebiotics on T2DM, their impact on gut microbiota composition, and the potential for personalized dietary interventions to optimize diabetes management and improve overall health outcomes. Full article

(This article belongs to the Special Issue Prebiotics, Probiotics, and Gut Microbiota with Chronic Disease—2nd Edition)

► Show Figures

Figure 1

16 pages, 1780 KiB

Open AccessReview

The Human Microbiome as a Therapeutic Target for Metabolic Diseases

by Thi Phuong Nam Bui

Nutrients 2024, 16(14), 2322; https://doi.org/10.3390/nu16142322 - 19 Jul 2024

Cited by 1 | Viewed by 2166

Abstract

The human microbiome functions as a separate organ in a symbiotic relationship with the host. Disruption of this host–microbe symbiosis can lead to serious health problems. Modifications to the composition and function of the microbiome have been linked to changes in host metabolic outcomes. Industrial lifestyles with high consumption of processed foods, alcoholic beverages and antibiotic use have significantly altered the gut microbiome in unfavorable ways. Therefore, understanding the causal relationship between the human microbiome and host metabolism will provide important insights into how we can better intervene in metabolic health. In this review, I will discuss the potential use of the human microbiome as a therapeutic target to improve host metabolism. Full article

(This article belongs to the Special Issue Prebiotics, Probiotics, and Gut Microbiota with Chronic Disease—2nd Edition)

► Show Figures

Journal Menu

Journal Browser

Prebiotics, Probiotics, and Gut Microbiota with Chronic Disease—2nd Edition

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Benefits of Publishing in a Special Issue

Published Papers (6 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI